Chennai: AstraZeneca’s Evusheld, a long-acting antibody combination for the prevention of Covid-19, retained neutralising activity against the Omicron SARS-CoV-2 variant, according to new preclinical data.
In this study, Evusheld’s Inhibitory Concentration 50, a measure of neutralising potency of an antibody, was 171 ng/ml and 277 ng/ml in two confirmatory tests, which is within the range of neutralising titres found in someone who has been previously infected with Covid-19.
Evusheld’s IC50 for the original strain of SARS-CoV-2, previously referred to as the Wuhan strain, was approximately 1.3 ng/ml and 1.5 ng/ml, respectively.
According to a statement, the early data, generated by pseudovirus testing of the full Omicron variant spike against the combination of tixagevimab with cilgavimab, the antibodies that comprise Evusheld, add to the growing body of preclinical evidence demonstrating that Evusheld retains activity against all tested variants of concern to date.